Search results for: 'research-area stem-cell hippo-signaling'
- Nintedanib (BIBF 1120)Catalog No. :A8252VEGFR/PDGFR/FGFR inhibitor
Nintedanib (BIBF 1120) is an indolinone-derived oral active, triple angiokinase inhibitor of vascular endothelial growth factor receptor (VEGFR)1-3, fibroblast growth factor receptor (FGFR)1-3 and platelet-derived growth factor receptor (PDGFR)α/β1. It has shown potent antiangiogenic activity at nanomolar (IC50, 20-100 nmol/L) by blocking these receptor-mediated signaling pathways1,2. Nintedanib (BIBF 1120) is in clinical development for the treatment of idiopathic pulmonary fibrosis as these receptors have been shown to be potentially involved in the pathogenesis of pulmonary fibrosis3,4. As a novel angiogenesis inhibitor, it is also being widely evaluated in different cancer models and has displayed significant anti-tumor activities by inhibiting tumor blood vessel formation5-7.
- PD168393Catalog No. :A2024EGFR inhibitorPD168393 is an irreversible kinase inhibitor of epidermal growth factor receptor (EGFR) with IC50 value of 0.70±0.09 nM and continued to have suppressed kinase activity after 8 hr in compound-free medium.
- PHA-680632Catalog No. :A4122Aurora kinase inhibitor,novel and potentPHA-680632 is a novel and potent inhibitor of Aurora kinases, a small family of serine/threonine kinases regulating mitosis in chromosome segregation and cell division, that inhibits the activity of all three Aurora kinases with 50% inhibition concentration IC50 values of 27 nM, 135 nM and 120 nM for Aurora A, B and C kinases respectively.